Contralateral prophylactic mastectomy and survival: report from the National Cancer Data Base, 1998–2002 Katharine YaoDavid J. WinchesterDezheng Huo Review 12 November 2013 Pages: 465 - 476
DNA from dead cancer cells induces TLR9-mediated invasion and inflammation in living cancer cells Johanna TuomelaJouko SandholmKatri S. Selander Preclinical Study 10 November 2013 Pages: 477 - 487
Role of HGF in obesity-associated tumorigenesis: C3(1)-TAg mice as a model for human basal-like breast cancer Sneha SundaramAlex J. FreemermanLiza Makowski Preclinical Study 12 November 2013 Pages: 489 - 503
A relative ordering-based predictor for tamoxifen-treated estrogen receptor-positive breast cancer patients: multi-laboratory cohort validation Xianxiao ZhouBailiang LiZheng Guo Preclinical study 20 November 2013 Pages: 505 - 514
Single-strand selective monofunctional uracil-DNA glycosylase (SMUG1) deficiency is linked to aggressive breast cancer and predicts response to adjuvant therapy Tarek M. A. Abdel-FatahNada AlbarakatiSrinivasan Madhusudan Preclinical study 20 November 2013 Pages: 515 - 527
Long non-coding RNA HOTAIR is an independent prognostic marker of metastasis in estrogen receptor-positive primary breast cancer Kristina P. SørensenMads ThomassenTorben A. Kruse Preclinical Study 21 November 2013 Pages: 529 - 536
Tamoxifen selects for breast cancer cells with mammosphere forming capacity and increased growth rate Diego RaffoDamian E. BerardiMarina Simian Preclinical study 21 November 2013 Pages: 537 - 548
Superior outcome after neoadjuvant chemotherapy with docetaxel, anthracycline, and cyclophosphamide versus docetaxel plus cyclophosphamide: results from the NATT trial in triple negative or HER2 positive breast cancer Xiaosong ChenGuolin YeKunwei Shen Clinical trial 14 November 2013 Pages: 549 - 558
Adjuvant tamoxifen-induced mammographic breast density reduction as a predictor for recurrence in estrogen receptor-positive premenopausal breast cancer patients Kyung Lan KoIn Suk ShinEun Sook Lee Clinical trial 14 November 2013 Pages: 559 - 567
Circulating hormones and breast cancer risk in premenopausal women: a randomized trial of low-dose tamoxifen and fenretinide Harriet JohanssonBernardo BonanniAndrea DeCensi Clinical trial 17 November 2013 Pages: 569 - 578
Comparing the outcome between multicentric and multifocal breast cancer: what is the impact on survival, and is there a role for guideline-adherent adjuvant therapy? A retrospective multicenter cohort study of 8,935 patients R. WoltersA. WöckelFor the BRENDA Study Group Clinical trial 21 November 2013 Pages: 579 - 590
Radiotherapy in implant-based immediate breast reconstruction: risk factors, surgical outcomes, and patient-reported outcome measures in a large Swedish multicenter cohort Max ErikssonLotta AnvedenJana de Boniface Clinical Trial 21 November 2013 Pages: 591 - 601
Use of the metastatic breast cancer progression (MBC-P) questionnaire to assess the value of progression-free survival for women with metastatic breast cancer Sara A. HurvitzDeepa LallaSusan D. Mathias Epidemiology Open access 12 November 2013 Pages: 603 - 609
Risk-reducing surgery increases survival in BRCA1/2 mutation carriers unaffected at time of family referral Sarah L. InghamMatthew SperrinD. Gareth R. Evans Epidemiology 20 November 2013 Pages: 611 - 618
Promoter methylation of BRCA1 in the prognosis of breast cancer: a meta-analysis Liang WuFengliang WangCheng Lu Epidemiology 21 November 2013 Pages: 619 - 627
Age related risk of myelodysplastic syndrome and acute myeloid leukemia among breast cancer survivors Henry G. KaplanJudith A. MalmgrenGregory S. Calip Epidemiology 22 November 2013 Pages: 629 - 636
Risk of GWAS-identified genetic variants for breast cancer in a Chinese population: a multiple interaction analysis Wei ChenHaiping SongXiaoping Miao Epidemiology 22 November 2013 Pages: 637 - 644
Cardiovascular disease among breast cancer survivors: the call for a clinical vascular health toolbox Lynnette M. JonesLee StonerBlair McLaren Brief Report 16 November 2013 Pages: 645 - 653
Addition of bevacizumab to three docetaxel regimens as adjuvant therapy for early stage breast cancer Denise A. YardleyLowell HartHoward Burris Brief Report 21 November 2013 Pages: 655 - 665
Assessing racial/ethnic disparities in chemotherapy treatment among breast cancer patients in context of changing treatment guidelines Abigail SilvaGarth H. RauscherCarol Estwing Ferrans Brief Report 22 November 2013 Pages: 667 - 672